Dr. Andrew X. Zhu is Director of Jiahui International Cancer Center, Director Emeritus of Liver Cancer Research at Massachusetts General Hospital Cancer Center, and Professor of Medicine at Harvard Medical School.
The major focus of his research is to develop more effective therapies for hepatocellular carcinoma (HCC), cholangiocarcinoma, and other gastrointestinal cancers.
Dr. Zhu has served as a principal investigator in many clinical trials in HCC and cholangiocarcinoma. An internationally recognized authority in HCC and cholangiocarcinoma, he led early efforts and pivotal studies of developing several molecularly targeted, immunotherapeutic agents, and combination regimens in liver cancers that received regulatory approval.
He is a founding member of the International Liver Cancer Association, a Fellow at the American College of Physicians, and a member of ASCO and AACR. Dr. Zhu has served on the Hepatobiliary Cancer committee of the National Comprehensive Cancer Network, the Grants Selection Committee of ASCO, the Hepatobiliary Cancer Task Force of The NCI Gastrointestinal Cancer Steering Committee, the American Joint Committee on Hepatobiliary Cancer Task Force, the Hepatocellular Carcinoma Practice Guidelines Committee of the American Association for the Study of Liver Diseases, and the Clinical Advisory Board of The Cholangiocarcinoma Foundation. He has received several awards for his work, including V Foundation Translational Research Award, Lorenzo Cappussotti Award, and Jonathan Kraft Translational Award.